Nasimi M, Garmaroudi G, Ghiasi M, Lajevardi V, Fooladi Z, Hassan Zadeh Tabatabaei MS, Ansari MS. Comorbidities in Patients with Lichen Planopilaris: A Case-Control Study.
Skin Appendage Disord 2022;
8:302-306. [PMID:
35983472 PMCID:
PMC9274992 DOI:
10.1159/000522371]
[Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2021] [Accepted: 01/25/2022] [Indexed: 09/29/2023] Open
Abstract
INTRODUCTION
Lichen planopilaris (LPP) is a lymphocyte-mediated type of scarring alopecia and considered to have autoimmune etiology. Studies about systemic comorbid conditions are limited. Our goal is to identify the prevalence of medical comorbidities in patients with LPP.
METHODS
In a retrospective case-control study, the medical records of 208 LPP patients and 208 controls were reviewed for existing comorbidities such as thyroid diseases, cardiovascular disorders, hypertension, hyperlipidemia, and lupus erythematous.
RESULTS
Hyperlipidemia was found in 41.8% of all patients with LPP and in 17.3% of controls (p value <0.001, OR = 4.167). Chances of hypertension and cardiovascular disorders were lower in the LPP group in comparison to controls (p value = 0.009). Thyroid disorders were more prevalent in LPP patients, but the difference was not statistically significant (p value = 0.277).
CONCLUSION
Our study further emphasizes that LPP patients should be screened for medical comorbidities, especially lipid profile abnormalities.
Collapse